2026-04-13T06:40:03Zhttps://recercat.cat/oai/request

oai:recercat.cat:2445/1940182025-12-05T14:13:04Zcom_2072_1057col_2072_478815col_2072_478917col_2072_478933

00925njm 22002777a 4500 dc Caballero Hernández, Ana Belén author Gámez Enamorado, Patrick author Sabaté Lagunas, Raimon author Espargaró Colomé, Alba author 2023-02-23T11:07:55Z 2023-12-31T06:10:22Z 2022 2023-02-23T11:07:56Z Amyloid aggregation is linked to a number of human disorders that range from non-neurological illnesses such as type 2 diabetes to neurodegenerative diseases such as Alzheimer's and Parkinson's diseases. The formation of insoluble protein aggregates with amyloid conformation inside bacteria, namely, in bacterial inclusion bodies, offers the possibility to use bacteria as simple models to study amyloid aggregation processes and potential effects of both anti-amyloid drugs and/or pro-aggregative compounds. This chapter describes fast, simple, inexpensive, highly reproducible, and tunable in vitro and in cellulo methods that use bacterial inclusion bodies as preliminary screening tools for anti-amyloid drugs. Keywords: Amyloid aggregation; Bacterial inclusion body; Conformational disease; Drug screening. Amiloïdosi Malaltia d'Alzheimer Amyloidosis Alzheimer's disease Anti-Amyloid Drug Screening Methods Using Bacterial Inclusion Bodies